Showing 1 - 10 of 8,958
concludes with a comparison of the state of the Polish system to the state of the systems in other European countries …
Persistent link: https://www.econbiz.de/10009511407
Ensuring equal access to the latest cancer medicines is one of the most pressing challenges facing OECD health systems today. Despite the emergence of new oncology drugs, disparities in patient access—particularly through clinical trials and early access programs—remain a critical issue....
Persistent link: https://www.econbiz.de/10015082000
functional and cognitive limitations. The comparison is performed following both a directly- and an indirectly-adjusted strategy …
Persistent link: https://www.econbiz.de/10013039883
Persistent link: https://www.econbiz.de/10013362440
At present coronavirus disease (COVID-19), an outbreak, calls for an emergency concern for public health internationally reported by the Director-General of WHO [1]. Nowadays, it stands for a universal crisis because the adverse effect of coronavirus proceeds to advance and continuously evolve...
Persistent link: https://www.econbiz.de/10014099763
This article argues that the European Court of Human Rights (ECtHR) seems to have recently acknowledged that there is a right to access to emergency health care in the member states of the Council of Europe. The Chamber of the ECtHR found that a state’s failure to design a regulatory framework...
Persistent link: https://www.econbiz.de/10014107983
COVID-19’s impact on business has been exasperating—but is it Frustrating? The Frustration doctrine of contract law excuses a party from its contractual obligations when an extraordinary event completely undermines the principal purpose of making the deal. This doctrine has long been a...
Persistent link: https://www.econbiz.de/10013235193
The COVID pandemic has underscored that IP can limit the ability to addressing public health crises because IP owners have the legal right to bar others from making needed supplies. However, what is less well understood yet critical to making medical treatments available are IP-related barriers...
Persistent link: https://www.econbiz.de/10014264033
Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry, however only a few biosimilars have been approved in the US since 2015, thereby largely preserving biologics...
Persistent link: https://www.econbiz.de/10014126235
In this paper we investigate the evolution of public European LTC systems in the forthcoming decades, using the Europe Future Elderly Model (EuFEM), a dynamic microsimulation model which projects the health and socio-economic characteristics of the 50 population of ten European countries,...
Persistent link: https://www.econbiz.de/10012956880